Roots-Analysis-Logo.png
The antiviral drugs market is anticipated to grow at a CAGR of 6.3% during the period 2022-2035, claims Roots Analysis
November 01, 2022 15:00 ET | Roots Analysis
London, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Antiviral Drugs Market, 2022 – 2035” report to its list of offerings. The recent COVID-19 pandemic has...
TIP_link_300x300.jpg
Virology Market Valuation to Outstrip $5.27Bn by 2028 Growth Projection at 3.6% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
September 21, 2021 08:51 ET | The Insight Partners
New York, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Virology Market: Key InsightsAccording to our latest study on “Virology Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type,...
Logo.png
Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
March 02, 2021 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering
August 26, 2020 17:35 ET | Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
CocrystalPharmaInc.jpg
Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event
December 04, 2019 08:00 ET | Cocrystal Pharma, Inc.
– Presentation on Tuesday, December 10th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage...
CocrystalPharmaInc.jpg
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
August 09, 2018 08:00 ET | Cocrystal Pharma, Inc.
– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for...
CocrystalPharmaInc.jpg
COCRYSTAL PHARMA, INC., PRICES $8,000,000 COMMON STOCK OFFERING
May 01, 2018 08:30 ET | Cocrystal Pharma, Inc.
TUCKER, GA and BOTHELL, WA, May 01, 2018 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP), (“Cocrystal” or the “Company”) a clinical stage biotechnology company focused on developing...